GTA-Glyceryltriacetate for Canavan Disease

• Status: Unknown status
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether oral supplementation of glyceryl triacetate improves the clinical prognosis of Canavan Disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center

Criteria

Inclusion Criteria:

• Age below 15 months

• Biochemically diagnosed with Canavan Disease

Exclusion Criteria:

• None